Unity Biotechnology
UBX was delisted on the 8th of July, 2025.
38 hedge funds and large institutions have $5.09M invested in Unity Biotechnology in 2024 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 4 increasing their positions, 10 reducing their positions, and 7 closing their positions.
354% more call options, than puts
Call options by funds: $109K | Put options by funds: $24K
9% more capital invested
Capital invested by funds: $4.66M → $5.09M (+$429K)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
0.02% less ownership
Funds ownership: 20.55% → 20.54% (-0.02%)
3% less funds holding
Funds holding: 39 → 38 (-1)
14% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 7
60% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BP
Ballentine Partners
Waltham,
Massachusetts
|
+$83.8K |
| 2 |
Renaissance Technologies
New York
|
+$42.7K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$20.9K |
| 4 |
UOC
UBS O'Connor
Chicago,
Illinois
|
+$10.8K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$568 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wells Fargo
San Francisco,
California
|
-$63.6K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$26.2K |
| 3 |
Millennium Management
New York
|
-$14.1K |
| 4 |
Morgan Stanley
New York
|
-$12.5K |
| 5 |
BlackRock
New York
|
-$10.6K |
UBX Hedge Fund Activity: Q3 2024 in Review
38 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Unity Biotechnology (UBX) for Q3 2024, worth a combined $5.09M — up 9.2% from $4.66M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of UBX and 6 opened new positions — a net loss of 1 holder — while 10 trimmed existing stakes and 4 added.
The largest buyer was Ballentine Partners, opening a new position worth an estimated $83.8K. The largest seller was Wells Fargo, cutting an estimated $63.6K.
- 38 institutional investors held Unity Biotechnology (UBX) as of Q3 2024, down from 39 in Q2 2024.
- Funds reported $5.09M of Unity Biotechnology stock for Q3 2024, up 9.2% quarter-over-quarter.
- 6 funds opened new Unity Biotechnology positions in Q3 2024 and 7 closed out, a net change of -1 holder.
- The largest Unity Biotechnology buyer in Q3 2024 was Ballentine Partners, an estimated $83.8K added.
- The largest Unity Biotechnology seller in Q3 2024 was Wells Fargo, an estimated $63.6K sold.
Based on aggregated 13F filings for Q3 2024.